ArticleDermatology and therapy2025

Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).

Emma Guttman-Yassky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.